TScan Therapeutics TCRX Income Statement (2020-2026)

NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST
Reported Financials

TScan Therapeutics Quarterly Income Statement

Periods 26 quarters
Latest Sep 2026
Industry Template General

TScan Therapeutics reported revenue of $0.59M and net income of -$33.09M for the quarter ended Sep 2026, down 76.7% year over year. This income statement covers 26 quarters of results from Jun 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
2.85M3.02M4.06M3.36M3.10M6.80M3.15M3.89M7.21M0.57M0.54M1.05M0.67M2.17M3.08M2.51M2.57M0.98M1.05M0.59M
Operating items
Research & DevelopmentR&D
12.61M14.69M14.49M15.03M15.60M21.78M21.23M22.74M22.41M24.86M26.88M26.26M29.35M29.79M32.63M31.69M20.04M21.90M23.40M25.29M
Selling, General & AdministrativeSG&A
4.45M4.49M4.81M4.91M6.14M7.77M6.53M5.89M6.16M7.08M7.77M7.41M8.02M8.63M9.10M7.87M6.39M8.22M8.14M8.33M
Operating ExpensesOpex
17.06M19.18M19.30M19.94M21.74M29.55M27.76M28.64M28.57M31.94M34.65M33.67M37.38M38.42M41.73M39.56M26.43M30.12M31.54M33.62M
Operating IncomeOp. Inc
-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M-23.86M-29.14M-30.49M-33.03M
Non-operating items
Non Operating Interest Expenses
0.20M0.98M0.96M0.97M0.98M0.85M0.96M0.95M0.96M0.78M0.68M0.69M0.70M0.70M0.69M0.70M0.78M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.06M0.01M0.00M
Interest & Investment IncomeInt & Inv Inc
0.00M0.01M0.15M0.53M0.90M1.14M1.53M2.73M2.60M2.19M3.41M3.69M2.78M2.80M2.39M2.04M1.58M1.16M0.83M0.72M
Other Non Operating IncomeOther Non Op Inc.
0.01M0.15M0.33M-0.07M0.18M0.57M1.75M1.74M1.23M2.45M2.74M0.90M2.12M1.70M1.34M0.88M0.47M0.13M-0.05M
Non Operating IncomeNon Op. Inc.
0.01M0.15M0.33M-0.07M0.18M0.57M1.75M1.74M1.23M2.45M2.74M0.90M2.12M1.70M1.34M0.88M0.47M0.13M-0.05M
Net income details
EBIT
-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M-23.86M-29.14M-30.49M-33.03M
EBT
-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M-22.98M-28.67M-30.36M-33.09M
Income After Tax
-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M-22.98M-28.67M-30.36M-33.09M
Income from Continuing OperationsIncome (Continuing)
-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M-22.98M-28.67M-30.36M-33.09M
Consolidated Net IncomeConsol Net Inc.
-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.76M-34.18M-36.95M-35.70M-22.98M-28.67M-30.36M-33.09M
Income towards Parent CompanyParent Net Inc
-14.20M-16.20M-15.10M-16.25M-18.72M-22.60M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.80M-34.13M-36.95M-35.71M-23.00M-28.67M-30.36M-33.10M
Net Income towards Common StockholdersNet Income
-14.20M-16.20M-15.10M-16.25M-18.72M-22.60M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.80M-34.13M-36.95M-35.71M-23.00M-28.67M-30.36M-33.10M
Additional items
EPS (Basic)
-1.22-0.68-0.63-0.67-0.78-0.93-0.51-0.24-0.30-0.32-0.28-0.25-0.32-0.26-0.28-0.28-0.18-0.22-0.23-0.25
EPS (Diluted)
-1.22-0.68-0.63-0.67-0.78-0.93-0.51-0.24-0.30-0.32-0.28-0.25-0.32-0.26-0.28-0.28-0.18-0.22-0.23-0.25
Shares Outstanding
11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M129.78M129.91M129.95M130.03M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M129.78M129.91M129.95M130.03M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M129.78M129.91M129.95M130.03M
EBITDA
-13.06M-14.97M-14.04M-15.33M-16.64M-21.24M-23.31M-23.46M-19.60M-30.12M-33.00M-31.60M-36.00M-35.57M-37.96M-36.29M-23.14M-28.45M-29.79M-32.35M
Interest ExpensesInt Expense
0.20M0.98M0.96M0.97M0.98M0.85M0.96M0.95M0.96M0.78M0.68M0.69M0.70M0.70M0.69M0.70M0.78M

TScan Therapeutics Income Statement API

Pull TScan Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TCRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY